Back to search results
NCT05805839

A Study of Imaging in Demyelinating Diseases

Enrolling by Invitation
PHASE2Ages 18+InterventionalDiagnostic
Mayo Clinic
~200 participants
Updated 2025-08-29 on ClinicalTrials.gov
What's tested:C-11 ER176 RadiotracerC11 Pittsburgh Compound BPET/CT scanMRI

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin
Measured over Baseline
+1 more outcome measured

Conditions

Multiple Sclerosis
Inflammatory Demyelinating Disease

Explore related trials

Inflammatory Demyelinating DiseaseMultiple Sclerosis

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Burcu Zeydan, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meet the requirements for one of the case or control groups.
MS patients undergoing neurologic evaluation procedures as part of Understanding Sex Differences in Multiple Sclerosis Spectrum of Demyelinating Disorders (IRB# 19-002807) Study or the Mayo Clinic Neurology Multiple Sclerosis Clinic.
Control participants without inflammatory-demyelinating diseases of the central nervous system
Capacity to sign consent.

Exclusion

Participants unable to lie down without moving for 20 minutes.
Women who are pregnant or cannot stop breast feeding for 24 hours.
For all patients and controls, any acute glucocorticoid (e.g., IV methylprednisolone or PO prednisolone) use within 2 weeks is an exclusion to limit medication interaction but preserve possible chronic systemic inflammation interaction with microglia activation metrics. Chronic disease modifying treatments in MS are allowed as these medications are not known to impact microglia activation.

What this trial measures

  • Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelinBaseline

    C-11 Pittsburgh compound-B (PiB) in PET imaging measured by PiB standardized uptake value ratio (SUVr)

  • Uptake of C-11 ER176 RadiotracerBaseline

    C-11 ER176 Radiotracer in TSPO PET imaging measured by ER176 SUVr